Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 13/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587422 | 0.93 | AR (0.37) | CETPS1PR1LTC4SARBRD4 | |
| SCHEMBL1588409 | 0.92 | CETP (0.46) | CETPS1PR1LTC4SAR | |
| SCHEMBL1588099 | 0.91 | CETP (0.45) | CETPS1PR1LTC4SAR | |
| SCHEMBL1588098 | 0.91 | CETP (0.40) | CETPLTC4SARCRHR1 | |
| SCHEMBL1587645 | 0.87 | CETP (0.36) | CETPS1PR1ARBRD4 | |
| SCHEMBL1587631 | 0.87 | CETP (0.39) | CETPBRD4PDK2 | |
| SCHEMBL4493410 | 0.86 | CYSLTR2 (0.38) | CETPS1PR1LTC4SCRHR1PDK2 | |
| SCHEMBL1588147 | 0.86 | CETP (0.41) | CETPBRD4PDK2 | |
| SCHEMBL1587427 | 0.85 | CETP (0.41) | CETPBRD4PDK2 | |
| SCHEMBL4498143 | 0.85 | CETP (0.38) | CETPS1PR1LTC4SARF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | CETP 1/4885S1PR1 1283/4885LTC4S 501/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885S1PR1 1283/4885LTC4S 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.